Last reviewed 2026-04-20 · How we verify

Degludec

At a glance

Approved indications

No approved indications tracked.

Boxed warnings

• WARNING: RISK OF THYROID C-CELL TUMORS • Liraglutide, one of the components of XULTOPHY 100/3.6, causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures in both genders of rats and mice. It is unknown whether XULTOPHY 100/3.6 causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans, as the human relevance of liraglutide-induced rodent thyroid C-cell tumors has not been determined [see Warnings and Precautions ( 5.1

Common side effects

• Nasopharyngitis
• Headache
• Nausea
• Diarrhea
• Increased Lipase
• Upper respiratory tract infection
• Hypoglycemia with glucose <54 mg/dL

Serious adverse events

• Severe Hypoglycemia
• Severe Gastrointestinal Adverse Reactions

Key clinical trials

• A Study of LY4057996 in Healthy Participants and Participants With Type 1 and Type 2 Diabetes (PHASE1)
• The Effect and Safety of a Novel CGM-Based Titration Algorithm for Basal Insulin in T2DM Participants. (NA)
• A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin (PHASE2)
• Regimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes (PHASE4)
• Evaluate the Efficacy and Safety of GZR101-80 Injection in Patients With Type 2 Diabetes (PHASE2)
• Single-ascending Dose Study of HEC-151 Injection (PHASE1)
• A Study of LY3938577 in Healthy Participants and Participants With Type 1 Diabetes Mellitus (T1DM) (PHASE1)
• A Research Study in Saudi Arabia to Understand How the Dose Check App Used With Tresiba Treatment Helps to Control Blood Sugar Level

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.